Table 2.
Dosimetric parameters
| No. of pts. | Mean ± SD | Min | Max | |
|---|---|---|---|---|
| Urethra D30 [Gy] at implantation (1) | 167 | 185.5 ± 6.7 | 159.8 | 204.5 |
| Prostate V [cc] at implantation (2) | 150 | 31.9 ± 11.3 | 12.8 | 63.0 |
| Prostate V [cc] postimplant (2) | 163 | 31.8 ± 11.1 | 13.8 | 61.4 |
| Prostate D90 [Gy] at implantation (3) | 167 | 185.5 ± 4.0 | 173.7 | 198.4 |
| Prostate D90 [Gy] postimplant (3) | 165 | 179.2 ± 16.3 | 118.6 | 210.6 |
| Prostate V100 [%] at implantation (4) | 167 | 99.6 ± 0.5 | 97.5 | 100 |
| Prostate V100 [%] postimplant (4) | 165 | 94.9 ± 3.8 | 80.7 | 100 |
| Prostate V90.6 [%] at implantation (5) | 167 | 99.9 ± 0.2 | 98.4 | 100 |
| Prostate V90.6 [%] postimplant (5) | 165 | 97.0 ± 3.8 | 64.5 | 100 |
| Rectum V100 [cc] at implantation (6) | 167 | 0.3 ± 0.2 | 0 | 1.2 |
| Rectum V100 [cc] postimplant (6) | 165 | 0.5 ± 0.6 | 0 | 3.2 |
(1) dose to 30% of the urethra.
(2) volume of the prostate.
(3) dose to 90% of the prostate.
(4) percentage volume receiving 100% of the prescription dose.
(5) percentage volume receiving 90.6% of the prescription dose.
(6) volume of the rectum receiving 100% of the prescription dose.